Nevirapine Lp Sandoz (Nevirapine)

Nevirapine binds to a non‑catalytic site on the HIV‑1 reverse transcriptase enzyme, causing a structural change that blocks the enzyme’s activity. This prevents the conversion of viral RNA into DNA, interrupting the replication cycle and limiting the production of new infectious virus particles.

The dosing regimen for Nevirapine is individualized by the prescribing clinician based on factors such as patient age, weight, treatment history, and co‑administered medications. Healthcare providers determine the appropriate dose and schedule in accordance with current clinical guidelines.

Nevirapine may be used during pregnancy when the benefits outweigh potential risks, but it is classified as a drug with limited safety data. Breastfeeding while on nevirapine should be discussed with a healthcare professional, as drug transfer to infant milk is possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nevirapine belongs to the NNRTI class, whereas alternatives such as protease inhibitors target a different viral enzyme. NNRTIs like nevirapine often have a simpler dosing schedule but may carry a higher risk of skin reactions, while protease inhibitors can have metabolic side effects. Choice depends on resistance patterns, tolerability, and patient‑specific factors.

Nevirapine Lp Sandoz should be stored at ambient temperature below 25 °C, protected from moisture and direct sunlight. Keep the product in its original packaging until use and avoid exposure to high humidity or extreme temperatures to maintain potency.

Nevirapine is administered orally, typically as a tablet taken with water. It is usually prescribed as part of a fixed‑dose combination or alongside other antiretroviral agents, and patients should follow the exact schedule and instructions provided by their healthcare provider.

The most serious risks include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and potentially life‑threatening hepatotoxicity. Early signs of rash or liver dysfunction require immediate medical evaluation and discontinuation of the drug.

Nevirapine is contraindicated in individuals with a known hypersensitivity to the drug or any of its components, and it should be avoided in patients with pre‑existing severe liver disease or a history of severe cutaneous adverse reactions. Clinicians must assess each patient’s medical history before initiating therapy.